The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
 
Shanu Modi
Honoraria - Daiichi Sankyo/Astra Zeneca; Seattle Genetics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seattle Genetics; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Roche/Genentech (Inst); Seattle Genetics (Inst)
 
William Jacot
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche; Seattle Genetics
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Rain Therapeutics; Roche; Seattle Genetics
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Taiho Pharmaceutical (Inst)
 
Joohyuk Sohn
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - Roche
 
Maria Vidal
Honoraria - Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Eriko Tokunaga
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly Japan
 
Junji Tsurutani
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo; Lilly
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Kirin (Inst); Lilly (Inst); MSD Oncology (Inst); Nihonkayaku (Inst); Pfizer (Inst); Sant Joan de Déu Research Foundation (Inst); West Japan Oncology Group (Inst); West Japan Oncology Group (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo; Novartis
 
Naoto T. Ueno
Honoraria - Amgen; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Henry Stewart Talks; Kyowa Hakko Kirin; Novartis; Pfizer; Puma Biotechnology; Rakuten Medical; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Immunomedics; Kechow Pharma; OncoCyte; Phoenix Molecular Designs; Takeda
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; Daiichi Sankyo; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Preferred Medicine; Puma Biotechnology; Sysmex
 
Yee Soo Chae
No Relationships to Disclose
 
Keun Seok Lee
Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Dong-A ST
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Nihon Medi-Physics; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan (Inst); Nihon Medi-Physics; Nippon Kayaku (Inst); Pfizer (Inst); Takeda
 
Yeon Hee Park
Honoraria - Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Novartis; Pfizer; Roche (Inst)
 
Xiaojia Wang
No Relationships to Disclose
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Dhiraj Gambhire
Employment - Daiichi Sankyo
Honoraria - Daiichi Sankyo; Pfizer
 
Lotus Yung
Employment - Daiichi Sankyo
 
Gerold Meinhardt
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Bayer; Daiichi Sankyo
 
Yibin Wang
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Daiichi-Sankyo; Exact Sciences; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seattle Genetics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seattle Genetics; West German Study Group (I)
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seattle Genetics (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)